Supplement × Prescription·Evidence index
PubMed indexes 6 records that name Aripiprazole and Cannabis (THC-Dominant) together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to Aripiprazole and Cannabis (THC-Dominant). It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
“Aripiprazole 10 mg/d could totally and durably suppress CIPSs in the patient, but had no effect on the smoking level. Treating CIPSs in ultrahigh risk individuals who cannot stop or refuse stopping cannabis might fit a harm-reduction strategy by preventing transition into psychosis.”
Names both Aripiprazole and Cannabis (THC-Dominant) in its title.
Names both Aripiprazole and Cannabis (THC-Dominant) in its title.
Names both Aripiprazole and Cannabis (THC-Dominant) in its title.
“Conclusions: Adolescents hospitalized for co-occurring psychosis and cannabis use disorder had a significantly longer length of stay and length of stay index. These data are consistent with a more rapid reduction in acute psychotic symptoms for aripiprazole compared with risperidone in the context of co-occurring cannabis use disorder.”
Names both Aripiprazole and Cannabis (THC-Dominant) in its title.
“The findings highlight the use of SGA for the treatment of psychotic symptoms in comorbidity with substance use. Future studies on people with dual diagnosis and focused on long-term evaluations are warranted and need to investigate the efficacy of newly introduced molecules, such as partial D2 agonists and longacting injectable antipsychotics.”
Names Aripiprazole and Cannabis (THC-Dominant) together in an interaction, co-administration, or pharmacokinetic context.
“In this case, precision-guided shared decision-making was associated with treatment continuity in early psychosis by resolving an atypical adverse effect and improving clinical and functional outcomes.”
Names Aripiprazole and Cannabis (THC-Dominant) together in an interaction, co-administration, or pharmacokinetic context.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Aripiprazole, Cannabis (THC-Dominant), and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
